8LY Stock Chart & Stats
€0.59
-€0.02(-7.82%)
At close: 4:00 PM EST
€0.59
-€0.02(-7.82%)
Day’s Range― - ―
52-Week Range€0.45 - €0.75
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€8.42M
Enterprise Value€79.68
Total Cash (Recent Filing)€935.00K
Total Debt (Recent Filing)€7.50M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding14,048,068
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-139.70
Price to Sales (P/S)30.78
P/FCF Ratio-6.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)€924.04K
Bulls Say, Bears Say
Bulls Say
Focused Product PipelineA tight focus on a single product candidate (BupiZenge™) concentrates R&D and commercial efforts, reducing dilution of management attention. For 2–6 months this clarity supports execution on regulatory, manufacturing and partnering milestones that drive durable value creation if clinical/commercial progress continues.
Commercialization And Partnering Business ModelA commercialization-plus-partnering model is structurally capital-efficient: licensing deals can supply upfront and milestone cash while royalties scale with partner reach. Over months this model preserves optionality to access distribution, share commercialization risk, and secure non-dilutive funding as clinical/regulatory steps are achieved.
Positive TTM Gross ProfitPositive gross profit implies that product unit economics or current activities can generate margin on sales. If sustained, this supports scalability: incremental revenue growth could flow through to operating leverage, making long-term margin recovery more attainable as SG&A and R&D are spread over higher sales.
Bears Say
Minimal Revenue, Heavy Net LossesExtremely low revenue versus very large operating losses indicates the company remains functionally pre-commercial or not generating sustainable sales. Over the coming months this disparity creates persistent financing needs and raises execution risk that revenue ramps may fail to offset ongoing burn without external support.
Persistent Heavy Cash BurnSubstantial negative operating and free cash flow signals ongoing consumption of liquidity to fund operations. This structural cash burn requires recurring external financing, which can dilute shareholders or increase leverage, and limits the company's ability to invest in commercialization or manufacturing capacity without secured funding.
Very High Leverage And Thin EquityA sharp shift from equity funding to meaningful debt creates elevated solvency and covenant risk. Extremely high debt-to-equity reduces financial flexibility, increases fixed obligations, and narrows options for partner negotiations or M&A over months, making funding stress and refinancing risk a persistent structural concern.
OncoZenge AB News
8LY FAQ
What was OncoZenge AB’s price range in the past 12 months?
OncoZenge AB lowest stock price was €0.45 and its highest was €0.75 in the past 12 months.
What is OncoZenge AB’s market cap?
OncoZenge AB’s market cap is €8.42M.
When is OncoZenge AB’s upcoming earnings report date?
OncoZenge AB’s upcoming earnings report date is Aug 27, 2026 which is in 21 days.
How were OncoZenge AB’s earnings last quarter?
OncoZenge AB released its earnings results on May 20, 2026. The company reported -€0.049 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is OncoZenge AB overvalued?
According to Wall Street analysts OncoZenge AB’s price is currently Overvalued.
Does OncoZenge AB pay dividends?
OncoZenge AB does not currently pay dividends.
What is OncoZenge AB’s EPS estimate?
OncoZenge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoZenge AB have?
OncoZenge AB has 14,048,068 shares outstanding.
What happened to OncoZenge AB’s price movement after its last earnings report?
OncoZenge AB reported an EPS of -€0.049 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.407%.
Which hedge fund is a major shareholder of OncoZenge AB?
Currently, no hedge funds are holding shares in DE:8LY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OncoZenge AB
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
Technical Analysis
―
―
Modus Therapeutics Holding AB
―
ExpreS2ion Biotech Holding AB
―
Sprint Bioscience AB
―